GRIM
LFCR icon

Greenhaven Road Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Greenhaven Road Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2M Sell
3,537,573
-145,000
-4% -$1M 9.05% 5
2025
Q4 		$30.1M Sell
3,682,573
-12,259
-0.3% -$90.7K 5.07% 4
2025
Q3 		$27.2M Hold
3,694,832
– – 4.01% 7
2025
Q2 		$30M Buy
3,694,832
+78,686
+2% +$530K 10.28% 3
2025
Q1 		$25.5M Hold
3,616,146
– – 10.38% 4
2024
Q4 		$26.9M Buy
3,616,146
+1,387,362
+62% +$8.86M 4.3% 5
2024
Q3 		$11M Buy
2,228,784
+12,660
+0.6% +$66.1K 4.67% 9
2024
Q2 		$11.4M Buy
2,216,124
+72,106
+3% +$427K 5.27% 7
2024
Q1 		$11.4M Sell
2,144,018
-222,938
-9% -$1.59M 4.82% 6
2023
Q4 		$14.7M Buy
2,366,956
+173,623
+8% +$1.21M 6.16% 6
2023
Q3 		$165K Buy
2,193,333
+290,694
+15% +$2.66M 8.3% 6
2023
Q2 		$184M Buy
1,902,639
+868,190
+84% +$5.3M 9.32% 5
2023
Q1 		$39M Buy
+1,034,449
New +$5.77M 2.24% 9

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greenhaven Road Investment Management's LFCR Position: Q1 2026 in Review

Greenhaven Road Investment Management reduced its Lifecore Biomedical (LFCR) stake by 3.9% in Q1 2026, selling an estimated $1M and leaving 3,537,573 shares worth $13.2M. The position accounts for 9.05% of the portfolio, ranked #5.

Greenhaven Road Investment Management first reported a position in LFCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $184M in Q2 2023. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Greenhaven Road Investment Management held 3,537,573 shares of Lifecore Biomedical worth $13.2M as of Q1 2026.
  • Greenhaven Road Investment Management sold 145,000 Lifecore Biomedical shares in Q1 2026, an estimated $1M.
  • Lifecore Biomedical made up 9.05% of Greenhaven Road Investment Management's portfolio in Q1 2026, its #5 holding.
  • Greenhaven Road Investment Management first reported a position in Lifecore Biomedical in Q1 2023 and has held it in 13 quarters since.
  • Greenhaven Road Investment Management's Lifecore Biomedical position peaked at $184M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Greenhaven Road Investment Management's 13F filing for Q1 2026, filed 15 May 2026.